> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# UCB Gets Expanded Pediatric Indication for Briviact
- URL: https://www.fdaweb.com/ucb-gets-expanded-pediatric-indication-for-briviact/
- Published: 2021-08-30T12:00:00.000Z
- Updated: 2026-09-14T17:12:27.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150038

FDA has approved a UCB expanded indication for Briviact (brivaracetam) tablets, oral solution, and injection to treat partial-onset seizures in patients as young as one month of age. The company says its data in pediatric patients includes long-term retention rates over two years. “In an open label follow-up pediatric study, an estimated 71.4% and 64.3% of patients, aged 1 month to those under age 17 years with partial-onset seizures (n=168), remained on treatment with Briviact at one and two years, respectively,” the company says. The drug was originally approved in 2016 as an add-on therapy for adult patients. It was approved as monotherapy for adults in 2017, and as monotherapy or adjunctive therapy in patients four years of age and older with partial-onset seizures in 2018.